Is Noiiglutide legal in the United Kingdom?

A Chinese long-acting GLP-1 agonist with published randomised multiple-dose data in obesity and a completed phase 3 in type 2 diabetes. Part of a development stream Western coverage largely ignores.

A substantial amount of GLP-1 development happens in China and is published in the same journals as everything else, and Western coverage of this field mostly proceeds as though it does not exist. Noiiglutide is one of several such programmes the catalogue now carries.

Mechanism: A long-acting agonist at the GLP-1 receptor, engineered for extended duration to allow infrequent subcutaneous dosing. Signalling is the same as the rest of the class: glucose-dependent insulin secretion, suppressed glucagon, delayed gastric emptying and reduced appetite through central GLP-1 receptors.

Regulatory history: Not approved in the United States. Developed in China, where regulatory status differs.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Noiiglutide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.